Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$31.50 USD
-6.36 (-16.80%)
Updated May 10, 2024 04:00 PM ET
After-Market: $31.05 -0.45 (-1.43%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
COLL 31.50 -6.36(-16.80%)
Will COLL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for COLL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COLL
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
COLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for COLL
Collegium downgraded by Piper Sandler over valuation
Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024
Collegium Pharmaceutical Reports First Quarter 2024 Earnings
Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews
Collegium Pharmaceutical (COLL) Gets a Buy from Truist Financial